Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02811783
Contact: Scott B Phillips, MD 8473628200 firstname.lastname@example.org
Contact: Heidi Fezatte, BS 8473628200 email@example.com
Sponsors and Collaborators
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Grace Ulerio firstname.lastname@example.org
Principal Investigator: Larisa Geskin, MD